The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the importance of individualized regimens that balance efficacy and safety, ...

Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...

The right clothing can help you minimize atopic dermatitis flares. Learn about common clothing triggers, plus tips on ...

The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...

Atopic dermatitis is one of the most common chronic inflammatory skin diseases worldwide and is also the most common form of eczema. Although infants and children are most often affected, adults can ...

Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...